Better Therapeutics announced today that, through a $113 million merger with Mountain Crest Acquisition Corp II, it will go public.
Mountain Crest, a publicly-traded, special purpose acquisition corporation (SPAC), will acquire Better Therapeutics in a deal expected to be completed in the summer of this year, with the company continuing to operate as Better Therapeutics while being listed on the Nasdaq under the BTTX ticker, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.